The Economic Times
English EditionEnglish Editionहिंदी संस्करण
| E-Paper
Search
+

    Glenmark Pharma launches nasal spray Ryaltris in India

    Synopsis

    Glenmark being one of the leaders in respiratory segment, has been the first to launch the branded generic version at an affordable cost for the treatment of allergic rhinitis in India.

    Agencies

    INSIGHTS

    Read Stock Insights by ET for a quick analysis

    Explore Now
    on Monday announced of launch its nasal spray Ryaltris, used for treatment of moderate to severe allergic rhinitis, in India.

    Glenmark being one of the leaders in respiratory segment, has been the first to launch the branded generic version at an affordable cost for the treatment of allergic rhinitis in India. This will provide patients a far more convenient, cost effective treatment option in the country, Glenmark said in a regulatory filing.

    "While the average cost of therapy of top 10 existing brands of the similar drug category is Rs 365, Glenmark's Ryaltris -AZ nasal spray has been launched at a breakthrough price of Rs 175 per pack of 75 metered doses (MD)," the company added.

    Alok Malik, Group Vice President and Business Head, India Formulations said: "Respiratory segment is a key area of focus for Glenmark and the launch of this product will enable us to improve access to allergic rhinitis treatment by providing an effective, convenient, world-class and affordable treatment option to patients in India".

    Shares of Glenmark Pharma were trading 0.14 per cent higher at Rs 577.45 apiece on BSE.
    (What's moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.)

    Download The Economic Times News App to get Daily Market Updates & Live Business News.

    Read before you invest. Insights on Glenmark Pharmaceuticals Ltd.. Explore Now
    The Economic Times

    Stories you might be interested in